WallStreetZenWallStreetZen

NASDAQ: CELC
Celcuity Inc Stock

$9.77+0.37 (+3.94%)
Updated Feb 3, 2023
CELC Price
$9.77
Fair Value Price
$13.62
Market Cap
$151.04M
52 Week Low
$4.81
52 Week High
$14.40
P/E
-4.11x
P/B
3.47x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$35.54M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.5
Operating Cash Flow
-$33M
Beta
0.79
Next Earnings
Mar 21, 2023
Ex-Dividend
N/A
Next Dividend
N/A

CELC Overview

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was founded in 2011 and is headquartered in Minneapolis, Minnesota.

Zen Score

Industry Average (30)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CELC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

CELC ($9.77) is undervalued by 28.26% relative to our estimate of its Fair Value price of $13.62 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
CELC ($9.77) is significantly undervalued by 28.26% relative to our estimate of its Fair Value price of $13.62 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
CELC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CELC due diligence checks available for Premium users.

Be the first to know about important CELC news, forecast changes, insider trades & much more!

CELC News

Valuation

CELC fair value

Fair Value of CELC stock based on Discounted Cash Flow (DCF)
Price
$9.77
Fair Value
$13.62
Undervalued by
28.26%
CELC ($9.77) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CELC ($9.77) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CELC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

CELC price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-4.11x
Industry
37.84x
Market
15.09x

CELC price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
3.47x
Industry
4.54x
CELC is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

CELC's financial health

Profit margin

Revenue
$0.0
Net Income
-$10.9M
Profit Margin
0%
CELC's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$65.3M
Liabilities
$21.8M
Debt to equity
0.5
CELC's short-term assets ($64.69M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CELC's short-term assets ($64.69M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CELC's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
CELC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$9.3M
Investing
-$12.1k
Financing
-$108.2k
CELC's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

CELC vs Diagnostic & Research Stocks

TickerMarket Cap1d %P/EP/B
CELC$151.04M+3.94%-4.11x3.47x
ANIX$141.31M-1.08%-10.16x4.86x
PRE$163.14M-2.65%-0.10x0.79x
BVS$163.25M-4.55%-1.02x0.48x
LAB$164.94M+1.96%-0.90x-2.63x

Celcuity Stock FAQ

What is Celcuity's quote symbol?

NASDAQ: CELC) Celcuity trades on the NASDAQ under the ticker symbol CELC. Celcuity stock quotes can also be displayed as NASDAQ: CELC.

If you're new to stock investing, here's how to buy Celcuity stock.

What is the 52 week high and low for Celcuity (NASDAQ: CELC)?

(NASDAQ: CELC) Celcuity's 52-week high was $14.40, and its 52-week low was $4.81. It is currently -32.16% from its 52-week high and 103.12% from its 52-week low.

How much is Celcuity stock worth today?

(NASDAQ: CELC) Celcuity currently has 15,459,739 outstanding shares. With Celcuity stock trading at $9.77 per share, the total value of Celcuity stock (market capitalization) is $151.04M.

Celcuity stock was originally listed at a price of $14.29 in Sep 20, 2017. If you had invested in Celcuity stock at $14.29, your return over the last 5 years would have been -31.63%, for an annualized return of -7.32% (not including any dividends or dividend reinvestments).

How much is Celcuity's stock price per share?

(NASDAQ: CELC) Celcuity stock price per share is $9.77 today (as of Feb 3, 2023).

What is Celcuity's Market Cap?

(NASDAQ: CELC) Celcuity's market cap is $151.04M, as of Feb 6, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Celcuity's market cap is calculated by multiplying CELC's current stock price of $9.77 by CELC's total outstanding shares of 15,459,739.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.